Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy aims to free thalassemia patients from lifelong blood transfusions

NCT ID NCT07489196

First seen Mar 27, 2026 · Last updated May 24, 2026 · Updated 8 times

Summary

This study tests a one-time gene therapy called CS-101 in 20 people aged 12 to 35 with severe β-thalassemia major who need regular blood transfusions. The goal is to see if the treatment is safe and can help patients produce enough healthy hemoglobin to stop needing transfusions for at least 12 months. Participants will be monitored for side effects and blood cell recovery after the infusion.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Β-THALASSEMIA MAJOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

    Contact

    Contact

  • Ruijin Hospital Shanghai JiaoTong University School of Medicine

    Shanghai, Shanghai Municipality, China

    Contact

    Contact

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.